"50%"@en . . . "Grepafloxacin exerts its antibacterial activity by inhibiting bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, essential enzymes for duplication, transcription, and repair of bacterial DNA."@en . . . . "119914-60-2"@en . . "withdrawn"@en . . "Drink liberally but avoid coffee."@en . . . "Rapidly and extensively absorbed following oral administration. The absolute bioavailability is approximately 70%."@en . . "15 ± 3 hours"@en . "Enteric bacteria and other eubacteria"@en . . "Grepafloxacin"@en . . . " "@en . . . "For treatment of adults with mild to moderate infections caused by susceptible strains of Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis."@en . . . . . . . . . "Take without regard to meals."@en . . "Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Grepafloxacin was withdrawn in the United States due to its side effect of lengthening the QT interval on the electrocardiogram, leading to cardiac events and sudden death. [Wikipedia]"@en . . . . . . . . . "Withdrawn from the US market in 1999 due to associations with QTc prolongation and adverse cardiovascular events."@en . . . . . . . . . " "@en . . . . "\"DrugSyn.org\":http://www.drugsyn.org/Grepafloxacin.htm"@en . . "Streptococcus pneumoniae"@en .